First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

10.1136/jitc-2021-002863

Saved in:

Bibliographic Details
Main Authors:	Piha-Paul, Sarina A, Geva, Ravit, Tan, Tira J, Lim, Darren Wt, Hierro, Cinta, Doi, Toshikiko, Rahma, Osama, Lesokhin, Alexander, Luke, Jason John, Otero, Javier, Nardi, Lisa, Singh, Angad, Xyrafas, Alexandros, Chen, Xinhui, Mataraza, Jennifer, Bedard, Philippe L
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Published:	BMJ 2022
Subjects:	antibodies clinical trials as topic combination drug therapy investigational neoplasm therapies Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Antineoplastic Combined Chemotherapy Protocols Dose-Response Relationship, Drug Female Glucocorticoid-Induced TNFR-Related Protein Humans Immune Checkpoint Inhibitors Lymphoma Male Maximum Tolerated Dose Middle Aged Neoplasms
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218496
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.1136/jitc-2021-002863